Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | SHBG | P04278 | 3/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3750366 | 0.83 | POLB (0.62) | POLBMAPTSHBGCYP17A1SMN1; SMN2 | |
| SCHEMBL9160890 | 0.81 | POLB (0.60) | POLBMAPTSHBGCYP17A1GRIN1 | |
| SCHEMBL12992189 | 0.78 | POLB (0.67) | POLBMAPTSHBGCYP17A1SMN1; SMN2 | |
| SCHEMBL15963152 | 0.78 | POLB (0.67) | POLBMAPTSHBGCYP17A1SMN1; SMN2 | |
| SCHEMBL2789952 | 0.78 | POLB (0.67) | POLBMAPTSHBGCYP17A1SMN1; SMN2 | |
| SCHEMBL15963511 | 0.78 | POLB (0.67) | POLBMAPTSHBGCYP17A1SMN1; SMN2 | |
| SCHEMBL23221135 | 0.77 | POLB (0.66) | POLBMAPTSHBGCYP17A1GRIN1 | |
| SCHEMBL23221194 | 0.77 | POLB (0.66) | POLBMAPTSHBGCYP17A1GRIN1 | |
| SCHEMBL9624018 | 0.76 | POLB (0.52) | POLBMAPTSHBGCYP17A1GRIN1 | |
| SCHEMBL9623918 | 0.76 | POLB (0.52) | POLBMAPTSHBGCYP17A1GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | BAYER SCHERING PHARMA AG (DE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292184-A1 | 17BETA-CYANO-19-ANDROST-4-ENE DERIVATIVE, ITS USE AND MEDICAMENTS COMPRISING THE DERIVATIVE | HSD17B11, HSD17B7, NR5A1 | POLB 824/4885MAPT 4345/4885SHBG 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.